Total Payments
$47,735
2024 Payments
$17,885
Companies
20
Transactions
71
Medicare Patients
1,011
Medicare Billing
$137,620
Payment Breakdown by Category
Consulting$29,425 (61.6%)
Other$9,300 (19.5%)
Travel$7,821 (16.4%)
Food & Beverage$1,189 (2.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $29,425 | 11 | 61.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $9,003 | 3 | 18.9% |
| Travel and Lodging | $7,821 | 24 | 16.4% |
| Food and Beverage | $1,189 | 32 | 2.5% |
| Compensation for serving as faculty or as a speaker for a medical education program | $297.39 | 1 | 0.6% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $25,737 | 28 | $0 (2024) |
| GENZYME CORPORATION | $6,207 | 3 | $0 (2021) |
| Janssen Scientific Affairs, LLC | $5,902 | 3 | $0 (2024) |
| Genentech USA, Inc. | $5,756 | 7 | $0 (2018) |
| ABBVIE INC. | $2,888 | 2 | $0 (2022) |
| AstraZeneca Pharmaceuticals LP | $549.93 | 5 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $194.86 | 6 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $110.11 | 1 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $81.51 | 2 | $0 (2023) |
| Tempus AI, Inc | $74.47 | 3 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $17,885 | 23 | PFIZER INC. ($11,364) |
| 2023 | $110.31 | 5 | Kite Pharma, Inc. ($28.63) |
| 2022 | $3,172 | 9 | ABBVIE INC. ($2,888) |
| 2021 | $6,125 | 1 | GENZYME CORPORATION ($6,125) |
| 2020 | $7,809 | 7 | PFIZER INC. ($7,809) |
| 2019 | $4,719 | 10 | PFIZER INC. ($4,476) |
| 2018 | $7,842 | 14 | Genentech USA, Inc. ($5,756) |
| 2017 | $74.17 | 2 | PFIZER INC. ($74.17) |
All Payment Transactions
71 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | Janssen Scientific Affairs, LLC | — | Consulting Fee | Cash or cash equivalent | $5,760.00 | General |
| 12/18/2024 | Janssen Scientific Affairs, LLC | — | Food and Beverage | In-kind items and services | $79.00 | General |
| 12/18/2024 | Janssen Scientific Affairs, LLC | — | Food and Beverage | In-kind items and services | $63.00 | General |
| 12/10/2024 | PFIZER INC. | ELREXFIO (Drug) | Consulting Fee | Cash or cash equivalent | $2,310.00 | General |
| Category: ONCOLOGY | ||||||
| 10/11/2024 | PFIZER INC. | ELREXFIO (Drug) | Consulting Fee | Cash or cash equivalent | $2,695.00 | General |
| Category: ONCOLOGY | ||||||
| 10/10/2024 | Tempus AI, Inc | XT CDX (Device) | Food and Beverage | In-kind items and services | $21.29 | General |
| Category: NONE | ||||||
| 09/16/2024 | Tempus AI, Inc | XT CDX (Device) | Food and Beverage | In-kind items and services | $23.27 | General |
| Category: NONE | ||||||
| 09/12/2024 | Takeda Pharmaceuticals U.S.A., Inc. | — | Food and Beverage | In-kind items and services | $110.11 | General |
| 07/16/2024 | PFIZER INC. | PADCEV (Biological) | Food and Beverage | In-kind items and services | $25.30 | General |
| Category: Oncology | ||||||
| 07/09/2024 | PFIZER INC. | ELREXFIO (Drug) | Consulting Fee | Cash or cash equivalent | $1,540.00 | General |
| Category: ONCOLOGY | ||||||
| 06/24/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $13.50 | General |
| Category: Oncology | ||||||
| 06/14/2024 | PFIZER INC. | ELREXFIO (Drug) | Consulting Fee | Cash or cash equivalent | $385.00 | General |
| Category: ONCOLOGY | ||||||
| 06/14/2024 | AstraZeneca Pharmaceuticals LP | — | Travel and Lodging | In-kind items and services | $18.88 | General |
| 06/07/2024 | Tempus AI, Inc | XT CDX (Device) | Food and Beverage | In-kind items and services | $29.91 | General |
| Category: NONE | ||||||
| 05/31/2024 | Daiichi Sankyo Inc. | INJECTAFER (Drug) | Food and Beverage | In-kind items and services | $24.48 | General |
| Category: Iron Deficiency Anemia | ||||||
| 05/21/2024 | Sirtex Medical Inc | SIR-Spheres Microspheres (Device) | Food and Beverage | Cash or cash equivalent | $33.15 | General |
| Category: Interventional Oncology | ||||||
| 04/19/2024 | PFIZER INC. | ELREXFIO (Drug) | Consulting Fee | Cash or cash equivalent | $2,310.00 | General |
| Category: ONCOLOGY | ||||||
| 04/12/2024 | AstraZeneca Pharmaceuticals LP | — | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $297.39 | General |
| 04/12/2024 | PFIZER INC. | ELREXFIO (Drug) | Travel and Lodging | Cash or cash equivalent | $224.73 | General |
| Category: ONCOLOGY | ||||||
| 03/06/2024 | PFIZER INC. | — | Travel and Lodging | In-kind items and services | $1,021.90 | General |
| 03/06/2024 | PFIZER INC. | — | Travel and Lodging | In-kind items and services | $652.96 | General |
| 03/06/2024 | PFIZER INC. | — | Travel and Lodging | In-kind items and services | $199.00 | General |
| 01/20/2024 | AstraZeneca Pharmaceuticals LP | — | Travel and Lodging | In-kind items and services | $47.42 | General |
| 11/21/2023 | Pharmacyclics LLC, An AbbVie Company | EPKINLY (Drug), IMBRUVICA | Food and Beverage | In-kind items and services | $22.51 | General |
| Category: ONCOLOGY | ||||||
| 11/13/2023 | PFIZER INC. | BOSULIF (Drug), COMIRNATY, ELREXFIO | Food and Beverage | In-kind items and services | $12.76 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 16 | 349 | 13,724 | $251,647 | $47,340 |
| 2022 | 11 | 271 | 3,588 | $253,844 | $62,880 |
| 2021 | 6 | 152 | 351 | $39,144 | $18,529 |
| 2020 | 9 | 239 | 468 | $44,656 | $8,871 |
Total Patients
1,011
Total Services
18,131
Medicare Billing
$137,620
Procedure Codes
42
All Medicare Procedures & Services
42 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 11 | 1,260 | $82,680 | $23,378 | 28.3% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 15 | 49 | $34,643 | $4,824 | 13.9% |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 2023 | 16 | 11,220 | $56,100 | $4,310 | 7.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 33 | 62 | $15,500 | $3,855 | 24.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 23 | 37 | $13,616 | $3,101 | 22.8% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 18 | 95 | $14,915 | $2,037 | 13.7% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 24 | 35 | $10,955 | $1,623 | 14.8% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 43 | 139 | $2,780 | $1,168 | 42.0% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 44 | 113 | $4,068 | $847.00 | 20.8% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 23 | 60 | $5,760 | $635.43 | 11.0% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 28 | 60 | $3,840 | $612.61 | 16.0% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 13 | 39 | $4,212 | $444.18 | 10.5% |
| 82728 | Ferritin (blood protein) level | Office | 2023 | 13 | 17 | $1,020 | $215.25 | 21.1% |
| 83550 | Iron binding capacity | Office | 2023 | 13 | 17 | $595.00 | $138.07 | 23.2% |
| 83540 | Iron level | Office | 2023 | 13 | 17 | $459.00 | $102.15 | 22.3% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2023 | 19 | 504 | $504.00 | $49.27 | 9.8% |
| J0897 | Injection, denosumab, 1 mg | Office | 2022 | 12 | 2,520 | $147,240 | $43,185 | 29.3% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2022 | 12 | 42 | $29,694 | $4,424 | 14.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 25 | 48 | $17,664 | $3,930 | 22.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 44 | 64 | $16,000 | $3,789 | 23.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 14 | 21 | $10,416 | $2,741 | 26.3% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2022 | 14 | 61 | $9,577 | $1,417 | 14.8% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2022 | 15 | 25 | $7,825 | $1,197 | 15.3% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 20 | 92 | $8,832 | $1,019 | 11.5% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2022 | 51 | 98 | $3,528 | $751.22 | 21.3% |
About Dr. Lalan Wilfong, MD
Dr. Lalan Wilfong, MD is a Medical Oncology healthcare provider based in Dallas, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/02/2006. The National Provider Identifier (NPI) number assigned to this provider is 1497793509.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Lalan Wilfong, MD has received a total of $47,735 in payments from pharmaceutical and medical device companies, with $17,885 received in 2024. These payments were reported across 71 transactions from 20 companies. The most common payment nature is "Consulting Fee" ($29,425).
As a Medicare-enrolled provider, Wilfong has provided services to 1,011 Medicare beneficiaries, totaling 18,131 services with total Medicare billing of $137,620. Data is available for 4 years (2020–2023), covering 42 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Other Specialties Hematology & Oncology
- Location Dallas, TX
- Active Since 06/02/2006
- Last Updated 04/07/2009
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1497793509
Products in Payments
- ELREXFIO (Drug) $9,465
- VENCLEXTA (Drug) $2,750
- NO PRODUCT DISCUSSED (Drug) $81.97
- XT CDX (Device) $74.47
- Trodelvy (Drug) $40.06
- SIR-Spheres Microspheres (Device) $33.15
- LUTATHERA (Drug) $25.48
- PADCEV (Biological) $25.30
- INJECTAFER (Drug) $24.48
- EPKINLY (Drug) $22.51
- KEYTRUDA (Biological) $20.93
- NERLYNX (Drug) $19.46
- Lenvima (Drug) $17.52
- SYNDROS (Drug) $15.86
- OPDIVO (Biological) $13.50
- BOSULIF (Drug) $12.76
- XTANDI (Drug) $11.54
- ELIQUIS (Drug) $11.49
- RETACRIT (Biological) $3.60
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Medical Oncology Doctors in Dallas
Dr. Moshe Levy, Md, MD
Medical Oncology — Payments: $5.0M
Medical Oncology $5.0M
Dr. Eric Nadler, Md, MD
Medical Oncology — Payments: $1.8M
Medical Oncology $1.8M
Dr. Joyce O'shaughnessy, Md, MD
Medical Oncology — Payments: $1.6M
Medical Oncology $1.6M
Dr. Thomas Hutson, Do,Pharmd, DO,PHARMD
Medical Oncology — Payments: $1.3M
Medical Oncology $1.3M
Dr. Tian Zhang, M.d, M.D
Medical Oncology — Payments: $395,066
Medical Oncology $395,066
Dr. Ashwani Agarwal, M.d, M.D
Medical Oncology — Payments: $304,262
Medical Oncology $304,262